Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study

被引：0
|
作者：
Coates, Laura [1 ]
Pillai, Sreekumar [2 ]
Hufford, Matthew M. [2 ]
Alves, Denise [2 ]
Park, So Young [2 ]
Gallo, Gaia [2 ]
Wu, Beilei [3 ]
Valter, Ivo [4 ]
Tahir, Hasan [5 ]
Chandran, Vinod [6 ]
Kavanaugh, Arthur [7 ]
Mease, Philip [8 ,9 ]
机构：
[1] Univ Oxford, Oxford, England
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] GCE Solut Inc, Bloomington, IL USA
[4] Ctr Clin & Basic Res, Tallinn, Estonia
[5] Whipps Cross Univ Hosp, Dept Rheumatol, London, England
[6] Univ Hlth Network, Univ Toronto, Krembil Res Inst, Div Rheumatol, Toronto, ON, Canada
[7] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[8] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[9] Univ Washington, Seattle, WA 98195 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1532
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study
    Coates, Laura
    Pillai, Sreekumar
    Zhang, Lu
    Adams, David
    Kerr, Lisa
    Hojnik, Maja
    Gallo, Gaia
    Valter, Ivo
    Tahir, Hasan
    Chandran, Vinod
    Mease, Philip
    Kavanaugh, Arthur
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] CONTINUING VERSUS WITHDRAWING IXEKIZUMAB IN PATIENTS WITH PSA WHO ACHIEVED SUSTAINED MINIMAL DISEASE ACTIVITY: RESULTS FROM THE SPIRIT-P3 STUDY
    Coates, Laura C.
    Pillai, Sreekumar G.
    Zhang, Lu
    Adams, David
    Kerr, Lisa
    Hojnik, Maja
    Gallo, Gaia
    Valter, Ivo
    Tahir, Hasan
    Chandran, Vinod
    Mease, Philip
    Kavanaugh, Arthur
    [J]. RHEUMATOLOGY, 2020, 59 : 120 - 120
  • [3] Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study
    Coates, Laura C.
    Pillai, Sreekumar G.
    Tahir, Hasan
    Valter, Ivo
    Chandran, Vinod
    Kameda, Hideto
    Okada, Masato
    Kerr, Lisa
    Alves, Denise
    Park, So Young
    Adams, David H.
    Gallo, Gaia
    Hufford, Matthew M.
    Hojnik, Maja
    Mease, Philip J.
    Kavanaugh, Arthur
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (09) : 1663 - 1672
  • [4] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 23 - 24
  • [5] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    [J]. JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 845 - 845
  • [6] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [7] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, V.
    Fleischmann, R.
    Lespessailles, E.
    Helliwell, P. S.
    Benichou, O.
    Erickson, J.
    Shuler, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 385 - 385
  • [8] Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials
    Behrens, Frank
    Nash, Peter
    Gossec, Laure
    Leage, Soyi Liu
    de la Torre, Inmaculada
    Sapin, Christophe
    Kurzawa, Monika
    Burmester, Gerd R.
    Smolen, Josef S.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [9] 52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Okada, Masan
    Kishimoto, Mitsumasa
    Shuler, Catherine
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan
    Lee, Chin
    Gladman, Dafna
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 925 - 925
  • [10] Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
    Combe, Bernard
    Emery, Paul
    Boonen, Annelies
    Leage, Soyi Liu
    Sapin, Christophe
    Bello, Natalia
    Dougados, Maxime
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345